drugset
drugset / Trial / NCT02486770

Study of Single Doses of IV Aerucin in Healthy Adults

NCT02486770 ↗

Phase 1 Completed 16 enrolled Aridis Pharmaceuticals, Inc.
Non-randomizedParallel-groupOpen-labelBasic science

Summary

This study will evaluate the safety profile and pharmacokinetic behavior of a single administration of Aerucin in healthy adults at three different dosages.

Timeline

Start
2015-04
Primary completion
2015-09
Completion
2015-09

Drugs

EvaluationDrugModalityDoseRoute
Subject AR-105 Unknown 2 mg/kg Intravenous
Subject AR-105 Unknown 8 mg/kg Intravenous
Subject AR-105 Unknown 20 mg/kg Intravenous

Indications

No indication recorded.